Show simple item record

dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorRehman, Shazza
dc.contributor.authorThatcher, Nick
dc.date.accessioned2009-08-10T10:46:59Z
dc.date.available2009-08-10T10:46:59Z
dc.date.issued2005-06
dc.identifier.citationErlotinib in non-small cell lung cancer: a review. 2005, 6 (6):995-1002 Expert Opin Pharmacotheren
dc.identifier.issn1744-7666
dc.identifier.pmid15952927
dc.identifier.doi10.1517/14656566.6.6.995
dc.identifier.urihttp://hdl.handle.net/10541/76807
dc.description.abstractErlotinib (Tarceva, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in cancer. Patients with advanced, incurable non-small cell lung cancer (NSCLC) may derive a clinical benefit from first- and second-line chemotherapy, but third-line treatment with available cytotoxic agents is not effective. Remarkably, EGFR/HER1 antagonists have demonstrated activity as second- and even third-line treatment for this disease. Erlotinib is the first of this novel class of drug to demonstrate a statistically significant and clinically relevant difference in overall survival, progression free survival and time to disease related symptoms (cough, pain, shortness of breath) compared with treatment with best supportive care in patients who have failed standard first- or second-line chemotherapy. This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAnimals
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshQuinazolines
dc.titleErlotinib in non-small cell lung cancer: a review.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uken
dc.identifier.journalExpert Opinion on Pharmacotherapyen
html.description.abstractErlotinib (Tarceva, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in cancer. Patients with advanced, incurable non-small cell lung cancer (NSCLC) may derive a clinical benefit from first- and second-line chemotherapy, but third-line treatment with available cytotoxic agents is not effective. Remarkably, EGFR/HER1 antagonists have demonstrated activity as second- and even third-line treatment for this disease. Erlotinib is the first of this novel class of drug to demonstrate a statistically significant and clinically relevant difference in overall survival, progression free survival and time to disease related symptoms (cough, pain, shortness of breath) compared with treatment with best supportive care in patients who have failed standard first- or second-line chemotherapy. This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC.


This item appears in the following Collection(s)

Show simple item record